ストックスクリーナーアプリを入手
52.41
0.58%
-0.355
前日終値:
$52.76
開ける：
$52.41
24時間の取引高:
226.03K
Relative Volume:
0.32
時価総額：
$2.25B
収益：
$4.85M
当期純損益:
$-114.75M
株価収益率:
-16.12
EPS:
-3.25
ネットキャッシュフロー:
$-100.36M
1週間 パフォーマンス:
+18.95%
1か月 パフォーマンス:
+23.11%
6か月 パフォーマンス:
+137.36%
1年 パフォーマンス:
+135.44%
1日の値動き範囲:
$51.47
$53.79
1週間の範囲:
$42.70
$54.00
52週間の値動き範囲:
$13.37
$54.00
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
DNTH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
52.44 | 2.26B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-14 | 開始されました | Truist | Buy |
| 2025-07-02 | 開始されました | William Blair | Outperform |
| 2024-12-20 | 開始されました | TD Cowen | Buy |
| 2024-10-03 | 開始されました | Oppenheimer | Outperform |
| 2024-07-26 | 開始されました | Robert W. Baird | Outperform |
| 2024-06-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-15 | 開始されました | Stifel | Buy |
| 2023-12-26 | 開始されました | Jefferies | Buy |
| 2023-11-22 | 開始されました | Wedbush | Outperform |
| 2023-10-30 | 開始されました | Guggenheim | Buy |
| 2023-09-28 | 開始されました | Raymond James | Outperform |
| 2022-08-25 | ダウングレード | Goldman | Buy → Neutral |
| 2022-01-06 | アップグレード | Goldman | Neutral → Buy |
| 2021-08-20 | 再開されました | Goldman | Neutral |
| 2021-08-03 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-22 | 繰り返されました | B. Riley Securities | Buy |
| 2021-06-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-05-18 | 開始されました | B. Riley Securities | Buy |
| 2021-01-07 | 開始されました | Mizuho | Buy |
| 2020-06-08 | アップグレード | Goldman | Neutral → Buy |
| 2019-03-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-03-15 | 開始されました | Raymond James | Outperform |
すべてを表示
Dianthus Therapeutics Inc (DNTH) 最新ニュース
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a Potential 23% Upside in the Biotech Sector - DirectorsTalk Interviews
Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 10.3%What's Next? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 46.6 USD By Investing.com - Investing.com India
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 46.6 USD - Investing.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 47.4% in December - MarketBeat
First Week of March 20th Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1%Should You Sell? - MarketBeat
Published on: 2026-01-15 20:27:08 - baoquankhu1.vn
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Is Dianthus Therapeutics Inc. currently under institutional pressureJuly 2025 Setups & Growth Oriented Trading Recommendations - bollywoodhelpline.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at $45.56 By Investing.com - Investing.com Nigeria
Trading Recap: How Dianthus Therapeutics Inc stock reacts to bond yieldsWeekly Stock Summary & Free Safe Capital Growth Stock Tips - Bộ Nội Vụ
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 12%Here's What Happened - MarketBeat
Breakout Zone: Whats the RSI of Dianthus Therapeutics Inc stock2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
Dianthus Therapeutics stock hits 52-week high at $45.56 - Investing.com
Fed Watch: How Dianthus Therapeutics Inc stock responds to policy changesJuly 2025 Snapshot & Weekly High Momentum Picks - Bộ Nội Vụ
Assessing Dianthus Therapeutics (DNTH) Valuation As Price To Book Sits Near 3x And Shares Show Mixed Returns - Yahoo Finance
Dianthus Therapeutics (DNTH) Investor Outlook: A Biotechnology Gem with a 66.92% Upside - DirectorsTalk Interviews
Will Dianthus Therapeutics Inc. stock gain from lower inflation2025 Institutional Moves & Low Risk Profit Maximizing Plans - Улправда
Can Dianthus Therapeutics Inc. stock hit record highs againJuly 2025 Sentiment & Risk Managed Investment Entry Signals - Улправда
Why Dianthus Therapeutics Inc. stock could outperform in 2025Portfolio Update Summary & Real-Time Volume Triggers - Улправда
DNTH: Analyst Raises Price Target to $63, Maintains Buy Rating | - GuruFocus
Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $63.00 - MarketBeat
Market Outlook: What technical charts say about Dianthus Therapeutics Inc. stock2025 Analyst Calls & Long-Term Investment Growth Plans - Улправда
Cash per share of Dianthus Therapeutics, Inc. – LS:A3ERZ4 - TradingView — Track All Markets
San Gabriel Valley Tribune - FinancialContent
Laser Focus WorldDianthus Therapeutics, Inc.Common Stock (Nasdaq:DNTH) Stock Quote - FinancialContent
Why Dianthus Therapeutics Inc. (87E) stock fits value portfolios2026 world cup usa national team quarterfinals goalkeepers high defensive line odds analysis breakdown - Улправда
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Dianthus Therapeutics Enters Oversold Territory (DNTH) - Nasdaq
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech targeting severe autoimmune diseases to present at JPM event - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.3% – Here’s Why - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.3%What's Next? - MarketBeat
Dianthus Therapeutics, Inc. $DNTH Stake Lessened by Moody Aldrich Partners LLC - MarketBeat
ETF Watch: Why Dianthus Therapeutics Inc stock could outperform in 2025Market Movement Recap & AI Enhanced Execution Alerts - moha.gov.vn
Dianthus, Nanjing Leads Biolabs initiate Phase 1 trial of LBL-047 - MSN
Leads Biolabs and Dianthus Therapeutics Initiate Phase 1 Trial for LBL-047 (DNTH212), a Bifunctional Fusion Protein Targeting Autoimmune Disorders - Quiver Quantitative
Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus - TradingView — Track All Markets
New lupus drug test begins, aiming for simple self-injections every month - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Given “Outperform” Rating at Wedbush - Defense World
Wedbush Reiterates Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics Earnings Notes - Trefis
How big funds are accumulating Dianthus Therapeutics Inc. (87E) stockPortfolio Return Report & High Conviction Investment Ideas - Улправда
Aug Closing: How big funds are accumulating Dianthus Therapeutics Inc. (87E) stockJuly 2025 Recap & Daily Profit Focused Screening - Улправда
Wall Street Recap: Is Dianthus Therapeutics Inc. stock overvalued by current metricsCPI Data & AI Enhanced Trading Signals - Улправда
First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Dianthus Therapeutics Inc (DNTH) 財務データ
収益
当期純利益
現金流量
EPS
4.38%
1.95%
大文字化:
|
ボリューム (24 時間):